Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mindbio Therapeutics Corp. ( (TSE:MBIO) ) has shared an update.
MindBio Therapeutics Corp. has successfully enrolled the final participant in its Phase 2B clinical trial for Major Depressive Disorder, marking a significant milestone in its mission to develop more effective mental health treatments. The trial involves 90 patients and utilizes an innovative design with sub-hallucinogenic microdoses of MB22001, offering a practical alternative to traditional high-dose psychedelic therapies. The company is the only one globally to have secured regulatory approvals for at-home patient-administered dosing in such trials, positioning it as a leader in the development of take-home psychedelic medicines. Additionally, MindBio has issued Restricted Stock Units to directors and staff in lieu of cash compensation, aligning its interests towards advancing MB22001 to Phase 3 trials.
More about Mindbio Therapeutics Corp.
MindBio Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on developing novel psychedelic-based medicines for mental health disorders. The company is committed to scientific rigor and patient accessibility, pioneering the use of microdosing to provide safe, effective, and scalable treatments for conditions such as depression and anxiety.
Average Trading Volume: 228,252
Technical Sentiment Signal: Sell
Learn more about MBIO stock on TipRanks’ Stock Analysis page.